-
Product Insights
Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Cancer - Drugs In Development, 2023’, provides an overview of the Squamous Non-Small Cell Lung Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MP-0310 in Pancreatic Cancer Drug Details: MP-0310 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPYK-04 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPYK-04 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SPYK-04 in Solid Tumor Drug Details:SPYK-04 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vinorelbine Tartrate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vinorelbine Tartrate in Solid Tumor report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-368 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-368 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABBV-368 in Ovarian Cancer Drug Details:ABBV-368 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-368 in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-368 in Malignant Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABBV-368 in Malignant Mesothelioma Drug Details:ABBV-368 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navtemadlin in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navtemadlin in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Navtemadlin in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...